OneSource Specialty Pharma Bets on GLP-1 Manufacturing Boom
OneSource Specialty Pharma, a Bengaluru-based Contract Development and Manufacturing Organisation (CDMO) demerged from Strides Pharma, is emerging as a key beneficiary of the global GLP-1 market expansion. With semaglutide patents nearing expiration in major markets, demand for injection pens is surging. The company projects revenue growth from $170 million in FY25 to $500 million by FY28, targeting 40% EBITDA margins. This aggressive scaling is driven by its Drug-Device Combinations segment, which manufactures sophisticated GLP-1 injection pens rather than generic drugs. OneSource is expanding cartridge capacity from 40 million to 220 million units by FY27, supported by long-term agreements with over 20 customers, including top global generic players. Its flagship facility holds rare USFDA approval for biologics fill-finish and device assembly, creating high switching costs for clients. The convergence of patent cliffs, rising GLP-1 demand, and a shift toward complex contract manufacturing positions OneSource for significant multi-year growth, transforming it from an overlooked entity into a strategic player in the pharmaceutical supply chain.
Wire timeline
OneSource Specialty Pharma Bets on GLP-1 Manufacturing Boom
OneSource Specialty Pharma, a Bengaluru-based Contract Development and Manufacturing Organisation (CDMO) demerged from Strides Pharma, is emerging as a key beneficiary of the global GLP-1 market expansion. With semaglutide patents nearing expiration in major markets, demand for injection pens is surging. The company projects revenue growth from $170 million in FY25 to $500 million by FY28, targeting 40% EBITDA margins. This aggressive scaling is driven by its Drug-Device Combinations segment, which manufactures sophisticated GLP-1 injection pens rather than generic drugs. OneSource is expanding cartridge capacity from 40 million to 220 million units by FY27, supported by long-term agreements with over 20 customers, including top global generic players. Its flagship facility holds rare USFDA approval for biologics fill-finish and device assembly, creating high switching costs for clients. The convergence of patent cliffs, rising GLP-1 demand, and a shift toward complex contract manufacturing positions OneSource for significant multi-year growth, transforming it from an overlooked entity into a strategic player in the pharmaceutical supply chain.
The Indian Express